Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes.
Smits, M M
Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes. [electronic resource] - Diabetic medicine : a journal of the British Diabetic Association 04 2017 - 591-592 p. digital
Publication Type: Letter; Research Support, Non-U.S. Gov't
1464-5491
10.1111/dme.13160 doi
Aged
Amylases--blood
Diabetes Mellitus, Type 2--drug therapy
Exenatide
Humans
Hypoglycemic Agents
Lipase--blood
Middle Aged
Peptides--adverse effects
Randomized Controlled Trials as Topic
Venoms--adverse effects
Glucagon-Like Peptide-1 Receptor Agonists
Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes. [electronic resource] - Diabetic medicine : a journal of the British Diabetic Association 04 2017 - 591-592 p. digital
Publication Type: Letter; Research Support, Non-U.S. Gov't
1464-5491
10.1111/dme.13160 doi
Aged
Amylases--blood
Diabetes Mellitus, Type 2--drug therapy
Exenatide
Humans
Hypoglycemic Agents
Lipase--blood
Middle Aged
Peptides--adverse effects
Randomized Controlled Trials as Topic
Venoms--adverse effects
Glucagon-Like Peptide-1 Receptor Agonists